Puma Biotechnology (PBYI) versus Qiagen (QGEN) Head to Head Review

Qiagen (NASDAQ: QGEN) and Puma Biotechnology (NASDAQ:PBYI) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current ratings for Qiagen and Puma Biotechnology, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen 0 7 5 0 2.42
Puma Biotechnology 0 1 8 0 2.89

Qiagen currently has a consensus price target of $33.50, suggesting a potential upside of 8.31%. Puma Biotechnology has a consensus price target of $130.67, suggesting a potential upside of 32.19%. Given Puma Biotechnology’s stronger consensus rating and higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than Qiagen.

Volatility & Risk

Qiagen has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Profitability

This table compares Qiagen and Puma Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Qiagen 6.40% 11.36% 6.37%
Puma Biotechnology -1,270.04% -310.69% -174.56%

Insider & Institutional Ownership

62.2% of Qiagen shares are held by institutional investors. Comparatively, 96.0% of Puma Biotechnology shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 21.1% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Qiagen and Puma Biotechnology’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qiagen $1.34 billion 5.28 $80.40 million $0.39 79.31
Puma Biotechnology N/A N/A -$276.01 million ($8.18) -12.08

Qiagen has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Summary

Qiagen beats Puma Biotechnology on 8 of the 13 factors compared between the two stocks.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply